Benign prostatic hyperplasia (BPH) is a urological disorder characterized by non-cancerous proliferation of prostate gland cells. This condition causes the gland to enlarge and, as a result, press against the urethra, constricting urine flow. This disorder is associated with aging, hormone imbalances, and abnormal cell growth.
The global benign prostatic hyperplasia market is expected to show considerable growth during the forecast period. This is attributed to rising geriatric population, increased awareness for prostate cancer and other urological disorders. However, the factors such as dearth of urologist in developing economies and lack of awareness regarding various urological diseases can hinder the growth of the market in the coming years.
The benign prostatic hyperplasia market is segmented by procedure type, by end user, and by geography. Based on procedure type, the market is segmented into transurethral resection of the prostate (TURP), transurethral microwave therapy (TUMT), transurethral needle ablation of the prostate (TUNA), laser surgery, prostatic stenting, and others. Additionally, the end user segment is futher segmentated into hospitals and clinics, ambulatory surgical centers(ASC), home, and others.
Geographically, the global benign prostatic hyperplasia market is segmented into North America, Europe, Asia-Pacific and Rest of the World (RoW) which consists of Latin America and Middle East & Africa. North America is account for the largest share of the benign prostatic hyperplasia market in 2016 due to high prevalence rate of benign prostatic hyperplasia. However, Asia is the fastest growing market due to the rise in various urological disorders and complications
Some of the major players in the global benign prostatic hyperplasia market include Endo International plc (U.S.), KARL STORZ GMBH & CO.KG (Germany), Lumenis (U.S.), Olympus corporation (Japan), Urologix, Inc. (U.S.), Boston Scientific corporation (U.S.), Coloplast A/S (Denmark), Lisa Laser (U.S.), Medifocus, Inc. (Canada) , Neotract, Inc. (U.S.), ProArc Medical LTD. (Israel), and Urotech GMBH (Germany), among others.
Table of Contents
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Markets Covered
1.3.2 Years Considered for the Study
2 Research Methodology
2.1 Research Methodology Steps
2.2 Secondary and Primary Research Methodology
2.2.1 Secondary Research
2.2.2 Primary Research
18.104.22.168 Key Data From Primary Sources
22.214.171.124 Key Insights From Primary Sources
126.96.36.199 Key Industry Insights
2.3 Market Size Estimation Methodology
2.4 Research Design
2.5 Market Data Validation and Triangulation
2.6 Assumptions for the Study
3 Executive Summary
4 Premium Insights
5 Market Overview
5.2 Market Segmentation
5.3 Market Dynamics
6 Benign Prostatic Hyperplasia Devices Market, By Procedure Type
6.2 Transurethral Resection of the Prostate (TURP)
6.3 Transurethral Microwave Therapy (TUMT)
6.4 Transurethral Needle Ablation of the Prostate (TUNA)
6.5 Laser Surgery
6.6 Prostatic Stenting
6.7 Other Procedure Type
*Note: Other Procedure Types Include Water-Induced Thermotherapy, High-Intensity Frequency Ultrasound, and Open Prostatectomy
7 Benign Prostatic Hyperplasia Devices Market, By End User
7.2 Hospitals and Clinics
7.3 Ambulatory Surgical Centers (ASC)
7.5 Other End Users
8 Global Benign Prostatic Hyperplasia Devices Market, By Region
8.2 North America
8.3.2 Rest of Europe (Roe)
9 Competitive Landscape
9.2 Competitive Situation and Trends
9.2.1 Agreements, Collaborations, and Partnerships
9.2.2 Product Launches
9.2.3 Client Acquisitions
9.2.6 Other Strategies
10 Company Profiles
(Overview, Financial*, Products & Services, Strategy, and Developments)
10.2 Endo International Plc
10.3 Karl Storz Gmbh & Co.Kg
10.5 Olympus Corporation
10.6 Urologix, Inc.
10.7 Boston Scientific Corporation
10.8 Coloplast A/S
10.9 Lisa Laser
10.10 Medifocus, Inc.
10.11 Neotract, Inc.
10.12 Proarc Medical Ltd.
10.13 Urotech Gmbh
*Details Might Not Be Captured in Case of Unlisted Companies.
11.1 Insights of Industry Experts
11.2 Discussion Guide
11.3 Company Developments (2013–2016)
11.4 Knowledge Store: Marketsandmarkets’ Subscription Portal
11.5 Introducing RT: Real-Time Market Intelligence
11.6 Available Customizations
11.7 Related Reports
1. All the Above Markets Will Be Provided for the Years 2014, 2015, 2016, and 2021
2. Revenue for Companies Listed Under “Company Profile” Section (Chapter 10) Might Not Be Captured for Companies Whose Financial Data is Not Available in Public Domain
3. the Above Scope is Tentative and is Subject to Change as the Research Progresses
Benchmarking the rapid strategy shifts of the Top 100 companies in the Benign Prostatic Hyperplasia Devices MarketRequest For Special Pricing